Bafna Pharmaceuticals Limited (NSE:BAFNAPH) — Stock Price
Bafna Pharmaceuticals Limited (NSE:BAFNAPH) is currently trading at Rs279.30 INR, down 2.00% today. Over the past 52 weeks, shares have ranged between Rs90.44 and Rs285.00. This page tracks Bafna Pharmaceuticals Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Bafna Pharmaceuticals Limited market cap and net worth.
Bafna Pharmaceuticals Limited (BAFNAPH) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bafna Pharmaceuticals Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bafna Pharmaceuticals Limited Income Statement — Revenue, Profit & Earnings by Year
Bafna Pharmaceuticals Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Revenue | Rs1.51 Billion | Rs1.46 Billion | Rs1.52 Billion | Rs1.15 Billion | Rs851.40 Million |
| Cost of Revenue | Rs1.30 Billion | Rs1.29 Billion | Rs1.07 Billion | Rs765.94 Million | Rs515.41 Million |
| Gross Profit | Rs201.42 Million | Rs168.77 Million | Rs452.15 Million | Rs387.56 Million | Rs338.60 Million |
| Research & Development | — | Rs21.94 Million | Rs15.36 Million | Rs7.21 Million | Rs14.73 Million |
| SG&A | — | Rs27.32 Million | Rs193.12 Million | Rs14.80 Million | Rs19.92 Million |
| Total Operating Expenses | Rs102.67 Million | Rs105.89 Million | Rs214.49 Million | Rs71.63 Million | Rs272.51 Million |
| Operating Income | Rs98.75 Million | Rs62.87 Million | Rs237.66 Million | Rs103.92 Million | Rs64.98 Million |
| EBITDA | Rs159.48 Million | Rs117.73 Million | Rs146.34 Million | Rs189.88 Million | Rs112.34 Million |
| EBIT | Rs98.75 Million | Rs68.84 Million | Rs96.38 Million | Rs136.54 Million | Rs57.41 Million |
| Interest Expense | Rs36.61 Million | Rs27.31 Million | Rs22.90 Million | Rs20.38 Million | Rs7.94 Million |
| Income Before Tax | Rs109.70 Million | Rs41.52 Million | Rs73.48 Million | Rs116.16 Million | Rs52.16 Million |
| Income Tax Expense | Rs-1.30 Million | — | Rs49.79 Million | Rs2.78 Million | Rs12.56 Million |
| Net Income | Rs111.00 Million | Rs41.52 Million | Rs73.48 Million | Rs113.38 Million | Rs52.16 Million |
Bafna Pharmaceuticals Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bafna Pharmaceuticals Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Assets | Rs1.76 Billion | Rs1.53 Billion | Rs1.48 Billion | Rs1.30 Billion | Rs901.45 Million |
| Total Current Assets | Rs896.52 Million | Rs847.28 Million | Rs944.70 Million | Rs873.12 Million | Rs508.80 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | Rs6.99 Million | — | — |
| Net Receivables | Rs440.07 Million | Rs401.96 Million | Rs453.95 Million | Rs411.49 Million | Rs147.80 Million |
| Inventory | Rs289.03 Million | Rs280.86 Million | Rs296.42 Million | Rs222.20 Million | Rs202.81 Million |
| Property, Plant & Equipment | — | — | — | — | Rs388.46 Million |
| Goodwill | — | — | — | — | Rs0.00 |
| Total Liabilities | Rs753.88 Million | Rs682.73 Million | Rs668.43 Million | Rs561.29 Million | Rs281.81 Million |
| Total Current Liabilities | Rs571.90 Million | Rs518.52 Million | Rs540.83 Million | Rs464.76 Million | Rs220.13 Million |
| Long-term Debt | — | Rs140.28 Million | Rs107.53 Million | Rs84.33 Million | Rs78.92 Million |
| Net Debt | Rs354.09 Million | Rs247.66 Million | Rs229.93 Million | Rs151.14 Million | Rs110.40 Million |
| Total Stockholder Equity | Rs961.50 Million | Rs848.07 Million | Rs808.39 Million | Rs734.55 Million | Rs619.64 Million |
| Retained Earnings | — | Rs-431.31 Million | Rs-451.75 Million | Rs-544.83 Million | Rs-659.74 Million |
Bafna Pharmaceuticals Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bafna Pharmaceuticals Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs118.27 Million | Rs195.29 Million | Rs94.85 Million | Rs49.52 Million | Rs97.28 Million |
| Capital Expenditures | Rs249.03 Million | Rs218.60 Million | Rs155.78 Million | Rs82.19 Million | Rs75.41 Million |
| Free Cash Flow | Rs-130.76 Million | Rs-23.31 Million | Rs-60.93 Million | Rs-32.66 Million | Rs21.87 Million |
| Investing Cash Flow | Rs-224.69 Million | Rs-213.02 Million | Rs-150.54 Million | Rs-74.93 Million | Rs-65.44 Million |
| Financing Cash Flow | Rs92.35 Million | Rs38.09 Million | Rs-8.45 Million | Rs101.77 Million | Rs-48.15 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Rs60.73 Million | Rs48.90 Million | Rs49.95 Million | Rs53.34 Million | Rs54.93 Million |
| Change in Cash | Rs-14.08 Million | Rs20.37 Million | Rs-64.13 Million | Rs76.36 Million | Rs-16.31 Million |
Bafna Pharmaceuticals Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Bafna Pharmaceuticals Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 25, 2026 | — | — | — |
| Feb 04, 2026 | — | — | — |
| Nov 10, 2025 | — | — | — |
| Aug 11, 2025 | — | — | — |
| May 26, 2025 | — | — | — |
| Feb 10, 2025 | — | — | — |
| Nov 07, 2024 | — | — | — |